查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495454

脑性肾上腺脑白质营养不良市场：按类型、最终用户划分 - 全球预测 2024-2030

Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

脑性肾上腺脑白质营养不良市场规模预计2023年为53.6亿美元，预计2024年将达到59.5亿美元，2030年将达到112.9亿美元，复合年增长率为11.21%。

脑性肾上腺脑白质营养不良 (CALD) 是一种罕见的性行为感染，主要影响神经系统和肾上腺（位于肾臟顶部的小器官）。 CALD 是脑白质营养不良的一种，是指一组以髓鞘变性为特征的疾病，髓磷脂是大脑和脊髓中神经纤维周围的保护鞘。提高对早期诊断的认识和筛检将改善结果并推动对有效治疗的需求。政府和监管机构透过资助和早期核准罕见疾病（包括 CALD）治疗方法提供的支持正在推动市场向前发展。然而，基因治疗和干细胞移植等治疗方法价格昂贵，因此市场拓展受到限制。此外，基因治疗和干细胞研究的技术进步提高了这些治疗方法的功效和安全性，正在为市场创造重大机会。

主要市场统计
基准年[2023] 53.6亿美元
预测年份 [2024] 59.5亿美元
预测年份 [2030] 112.9亿美元
复合年增长率（%） 11.21%

区域洞察

美洲地区在医疗保健和研究方面拥有强大的基础设施，并采取了许多旨在早期发现和治疗 CALD 的措施。一些国家新生儿筛检计画的进步加强了早期诊断，从而改善了受影响个体的长期预后。对基因疗法和其他创新疗法的投资正在显示出有希望的结果，专利反映出标靶治疗的持续改进。欧盟拥有强大的法律规范，支持广泛的研究和新治疗方法的采用。德国、法国和荷兰等国家製定了积极的新生儿筛检计划，并在 CALD 相关研究和临床试验方面处于领先地位。欧洲药品管理局 (EMA) 在加速创新治疗方法的核准方面发挥关键作用。随着阿联酋和沙乌地阿拉伯等国家投资医疗基础设施和专家培训项目，中东地区对 CALD 的认识和资源不断增加。亚太地区基因组学和生物技术领域正在快速发展，各国积极投资和资金筹措。亚太地区国家拥有强大的製药业和政府支持的医疗保健系统，支持先进的研究和治疗方法。

FPNV定位矩阵

FPNV 定位矩阵对于评估脑性肾上腺脑白质营养不良市场中供应商的定位至关重要。此矩阵提供了对供应商的全面评估，并检查了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对脑性肾上腺脑白质营养不良市场供应商的当前状态进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该领域竞争性质的宝贵见解，包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对脑肾上腺脑白质营养不良市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • CALD 的盛行率和诊断率不断提高
      • 扩大医疗费用和保险范围
    • 抑制因素
      • 高治疗成本和进入问题
    • 机会
      • 药物开发的进展
      • 改善基因治疗以达到精准治疗
    • 任务
      • 脑性肾上腺脑白质营养不良治疗产品开发与製造的复杂性
  • 市场区隔分析
    • 类型：基因检测的持续创新加速脑性肾上腺脑白质营养不良的诊断
    • 最终使用者：专科诊所在持续管理和专业治疗中发挥重要作用。
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章脑性肾上腺脑白质营养不良市场：依类型

  • 诊断
  • 治疗

第七章脑性肾上腺脑白质营养不良市场：依最终用户

  • 居家照护服务
  • 医院和临床
  • 专科诊所

第八章北美及南美脑性肾上腺脑白质营养不良市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区脑性肾上腺脑白质营养不良市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲脑性肾上腺脑白质营养不良市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Neurocode 推出 ALZpath Dx 血液检测，这是阿兹海默症诊断的突破
    • InSilicoTrials Technologies 与 Axoltis Pharma 之间的策略联盟加强中枢神经系统药物开发
    • FDA核准Lerigtazone 治疗脑性肾上腺脑白质营养不良的 3 期 CALYX 研究
  • 战略分析和建议

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-CD5A9334D6B7

[181 Pages Report] The Cerebral Adrenoleukodystrophy Market size was estimated at USD 5.36 billion in 2023 and expected to reach USD 5.95 billion in 2024, at a CAGR 11.21% to reach USD 11.29 billion by 2030.

Cerebral adrenoleukodystrophy (CALD) is a rare genetic infection that mainly affects the nervous system and adrenal glands, which are small organs on top of each kidney. CALD is a type of leukodystrophy, which refers to a group of disorders characterized by the degeneration of myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. Increased awareness and better screening practices for early diagnosis can lead to improved outcomes, thereby driving the demand for effective treatments. Government and regulatory support through funding and fast-track approvals for treatments of rare diseases, including CALD, driving the market forward. However, the high cost associated with treatments such as gene therapy and stem cell transplantation limits the market expansion. Furthermore, technological advancements in gene therapy and stem cell research that increase the effectiveness and safety of these treatments pose significant opportunities to the market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.36 billion
Estimated Year [2024] USD 5.95 billion
Forecast Year [2030] USD 11.29 billion
CAGR (%) 11.21%

Regional Insights

The American region exhibits a strong infrastructure in healthcare and research, with numerous initiatives aiming at early detection and treatment of CALD. Advances in newborn screening programs across several countries have enhanced early diagnosis, thereby improving the long-term prognosis of affected individuals. Investments in gene therapy and other innovative treatments have shown promising results, with patents reflecting ongoing improvements in targeted therapies. The EU has a strong regulatory framework that supports extensive research and the adoption of new therapies. Countries including Germany, France, and the Netherlands have active newborn screening programs and are leaders in research and clinical trials related to CALD. The European Medicines Agency (EMA) plays an important role in the rapid approval of innovative treatments. Awareness and resources for CALD are growing in the Middle East, with countries including the UAE and Saudi Arabia investing in healthcare infrastructure and specialist training programs. The APAC region is rapidly advancing in the fields of genomics and biotechnology, with substantial countries' investments & funding directed toward genetic research. The APAC countries with a strong pharmaceutical sector and government-backed healthcare system support advanced research and treatment methodologies.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cerebral Adrenoleukodystrophy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increased prevalence and diagnostic rates of CALD
      • Growing healthcare expenditure and insurance coverage
    • Market Restraints
      • High cost of treatment and accessibility issues
    • Market Opportunities
      • Advancements in therapeutic product development
      • Improvements in gene therapy for precision treatment
    • Market Challenges
      • Product development and manufacturing complexities in cerebral adrenoleukodystrophy treatment
  • Market Segmentation Analysis
    • Type: Ongoing innovations in genetic testing to accelerate the diagnosis of cerebral adrenoleukodystrophy
    • End-User: Specialty clinics play a significant role in ongoing management and specialized treatments.
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cerebral Adrenoleukodystrophy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cerebral Adrenoleukodystrophy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Breakthrough in Alzheimer's Disease Diagnosis as Neurocode Launch ALZpath Dx Blood Test

Neurocode announced the clinical release of ALZpath Dx, a cutting-edge blood test designed to detect, diagnose, and monitor Alzheimer's disease (AD). This test measured the circulating levels of phosphorylated tau at position 217 (pTau217), a key biomarker for AD. Utilizing Quanterix Corp's Simoa(R) technology, ALZpath Dx offered a non-invasive, cost-effective, and highly accurate diagnostic alternative to traditional methods like brain imaging or cerebrospinal fluid tests. [Published On: 2024-03-04]

Strategic Collaboration between InSilicoTrials Technologies and Axoltis Pharma to Enhance CNS Drug Development

InSilicoTrials Technologieshas formed a strategic partnership with Axoltis Pharma, which is focused on advancing treatments for neurodegenerative conditions. This collaboration centers around employing InSilicoTrials Technologies's platform, particularly its InSilicoNEURO suite, to explore the effects of Axoltis Pharma's NX210c, a 12-amino acid peptide, on virtual patients with various Central Nervous System (CNS) disorders including Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease, and Multiple Sclerosis. [Published On: 2023-07-27]

FDA Approves Phase 3 CALYX Trial for Leriglitazone in Treatment of Cerebral Adrenoleukodystrophy

MINORYX THERAPEUTICS SL has gained approval from the US FDA for its Phase 3 CALYX trial, focusing on leriglitazone as a therapeutic option for adult male patients with cerebral Adrenoleukodystrophy (cALD), a subtype of X-linked Adrenoleukodystrophy (X-ALD). The primary study endpoint included major outcomes such as 'time to death' or 'permanent ventilatory support. Endpoints were built on favorable previous trial outcomes and ongoing compassionate use data. Leriglitazone has shown promise in halting lesion progression, achieving stabilizations paralleled to those seen in hematopoietic stem cell transplant or gene therapy treatments. [Published On: 2023-05-31]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cerebral Adrenoleukodystrophy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cerebral Adrenoleukodystrophy Market, highlighting leading vendors and their innovative profiles. These include bluebird bio, Inc., Boston Scientific Corporation, Esaote S.p.A, FUJIFILM Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic PLC, MINORYX THERAPEUTIS SL, NeuroVia, Inc., Neusoft Corporation, POXEL SA, SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD., Shimadzu Corporation, Siemens AG, Stryker Corporation, and Toshiba Corporation.

Market Segmentation & Coverage

This research report categorizes the Cerebral Adrenoleukodystrophy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Diagnosis
      • Blood Tests
      • Genetic Testing
      • MRI
      • Neurological Tests
    • Treatment
      • Adrenal Hormone Replacement
      • Gene Therapy
      • Stem Cell Transplantation
  • End-User
    • Home Care Services
    • Hospitals & Clinical
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased prevalence and diagnostic rates of CALD
      • 5.1.1.2. Growing healthcare expenditure and insurance coverage
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and accessibility issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapeutic product development
      • 5.1.3.2. Improvements in gene therapy for precision treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Product development and manufacturing complexities in cerebral adrenoleukodystrophy treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Ongoing innovations in genetic testing to accelerate the diagnosis of cerebral adrenoleukodystrophy
    • 5.2.2. End-User: Specialty clinics play a significant role in ongoing management and specialized treatments.
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cerebral Adrenoleukodystrophy Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnosis
  • 6.3. Treatment

7. Cerebral Adrenoleukodystrophy Market, by End-User

  • 7.1. Introduction
  • 7.2. Home Care Services
  • 7.3. Hospitals & Clinical
  • 7.4. Specialty Clinics

8. Americas Cerebral Adrenoleukodystrophy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cerebral Adrenoleukodystrophy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cerebral Adrenoleukodystrophy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Breakthrough in Alzheimer's Disease Diagnosis as Neurocode Launch ALZpath Dx Blood Test
    • 11.3.2. Strategic Collaboration between InSilicoTrials Technologies and Axoltis Pharma to Enhance CNS Drug Development
    • 11.3.3. FDA Approves Phase 3 CALYX Trial for Leriglitazone in Treatment of Cerebral Adrenoleukodystrophy
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET RESEARCH PROCESS
  • FIGURE 2. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CEREBRAL ADRENOLEUKODYSTROPHY MARKET DYNAMICS
  • FIGURE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. CEREBRAL ADRENOLEUKODYSTROPHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY MRI, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY MRI, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NEUROLOGICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NEUROLOGICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADRENAL HORMONE REPLACEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADRENAL HORMONE REPLACEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS & CLINICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS & CLINICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN CEREBRAL ADRENO